Top

Published in:

01-09-2018 | Editorial

A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?

Authors: Ayesha Shah, Mark Morrison, Gerald Holtmann

Published in: Indian Journal of Gastroenterology | Issue 5/2018

Excerpt

In this issue of the Indian Journal of Gastroenterology, the group of Ghoshal et al. [1] present data of a randomized, placebo-controlled study targeting the gastrointestinal (GI) microbiome in patients with chronic constipation that demonstrates remarkable effects and at the same time has explored the potential mechanisms of action. …

Ghosal UC, Srivastava D, Misra A. A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and shortening colon transit time: a pilot study. Indian J Gastroenterol. 2018; 37: https://doi.org/10.1007/s12664-018-0901-6.

Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–79.CrossRef

Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2:1437–42.CrossRef

Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693–702.CrossRef

Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8.CrossRef

Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213–24.CrossRef

Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–9.e6.CrossRef

Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22–8.

Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol. 2011;25:3–18.CrossRef

10.

Andresen V, Enck P, Frieling T, et al. S2k guideline for chronic constipation: definition, pathophysiology, diagnosis and therapy. Z Gastroenterol. 2013;51:651–72.CrossRef

11.

Wald A. Constipation: pathophysiology and management. Curr Opin Gastroenterol. 2015;31:45–9.CrossRef

12.

Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25 Suppl B:11b–5b.CrossRef

13.

Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580–7.CrossRef

14.

Alsalimy N, Madi L, Awaisu A. Efficacy and safety of laxatives for chronic constipation in long-term care settings: a systematic review. J Clin Pharm Ther. 2018;43:595–605.CrossRef

15.

Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRef

16.

Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–96.CrossRef

17.

Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–36.CrossRef

18.

Black CJ, Burr NE, Quigley EM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2018.08.021.

19.

Pare P, Fedorak RN. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Can J Gastroenterol Hepatol. 2014;28:549–57.CrossRef

20.

Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–70.CrossRef

21.

So D, Whelan K, Rossi M, et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. Am J Clin Nutr. 2018;107:965–83.CrossRef

22.

Wilder-Smith CH, Olesen SS, Materna A, et al. Fermentable sugar ingestion, gas production, and gastrointestinal and central nervous system symptoms in patients with functional disorders. Gastroenterology. 2018;155:1034–44.e6.CrossRef

23.

Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100:1075–84.CrossRef

24.

Martinez-Martinez MI, Calabuig-Tolsa R, Cauli O. The effect of probiotics as a treatment for constipation in elderly people: a systematic review. Arch Gerontol Geriatr. 2017;71:142–9.CrossRef

25.

Muller-Lissner S, Tack J, Feng Y, et al. Levels of satisfaction with current chronic constipation treatment options in Europe - an internet survey. Aliment Pharmacol Ther. 2013;37:137–45.CrossRef

26.

Attaluri A, Jackson M, Valestin J, Rao SSC. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010;105:1407–11.CrossRef

27.

Parthasarathy G, Chen J, Chen X, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150:367–79.e1.CrossRef

28.

Ghoshal U, Shukla R, Srivastava D, Ghoshal UC. Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in methanobrevibacter smithii, which is associated with higher methane production. Gut Liver. 2016;10:932–8.CrossRef

29.

Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612–8.CrossRef

30.

Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1089–95.CrossRef

31.

Fiedorek SC, Pumphrey CL, Casteel HB. Breath methane production in children with constipation and encopresis. J Pediatr Gastroenterol Nutr. 1990;10:473–7.CrossRef

32.

Peled Y, Weinberg D, Hallak A, Gilat T. Factors affecting methane production in humans. Gastrointestinal diseases and alterations of colonic flora. Dig Dis Sci. 1987;32:267–71.CrossRef

33.

Hwang L, Low K, Khoshini R, et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Dig Dis Sci. 2010;55:398–403.CrossRef

34.

Kim G, Deepinder F, Morales W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012;57:3213–8.CrossRef

35.

Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn’s disease. Gut. 2017;66:813–22.CrossRef

36.

Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309–25.CrossRef

37.

Nkamga VD, Henrissat B, Drancourt M. Archaea: essential inhabitants of the human digestive microbiota. Hum Microbiome J. 2017;3:1–8.CrossRef

Title: A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?
Authors: Ayesha Shah
Mark Morrison
Gerald Holtmann
Publication date: 01-09-2018
Publisher: Springer India
Published in: Indian Journal of Gastroenterology / Issue 5/2018
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI: https://doi.org/10.1007/s12664-018-0912-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2018

Assessment of stool frequency and colonic transit time in Indian children with functional constipation and healthy controls

Distal pancreatectomy with autologous islet transplantation in chronic pancreatitis patients: First case series from India

All that a physician should know about gluten-free diet

Utility of multiplex polymerase chain reaction (PCR) in diarrhea—An Indian perspective

Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study

Basal lower esophageal sphincter pressure in gastroesophageal reflux disease: An ignored metric in high-resolution esophageal manometry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page